GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
IsoRay Inc. (ISR) [hlAlert]

Rating:
Buy ISR
up 153.70 %

IsoRay Inc. (ISR) rated Buy with price target $5 by Maxim Group

Posted on: Wednesday,  Jul 16, 2014  12:00 AM ET by Maxim Group

Maxim Group rated Buy IsoRay Inc. (AMEX: ISR) on 07/16/2014. Previously Maxim Group rated Buy IsoRay Inc. (AMEX: ISR) on 11/01/2013.,
when the stock price was $0.54. Since then, IsoRay Inc. has gained 153.70% as of 08/27/2015's recent price of $1.37.
If you would have followed the previous Maxim Group's recommendation on ISR, you would have gained 153.7% of your investment in 664 days.

IsoRay, Inc. is engaged in the development of permanent seed brachytherapy in the treatment of cancers. IsoRay, Inc. has obtained clearance from the United States Food and Drug Administration (FDA) for treatment for all solid tumor applications using Cesium-131 (Cs-131). Such applications include prostate cancer; ocular melanoma; head, neck and lung tumors; and breast, liver, brain and pancreatic cancer. The seed may be used in surface, interstital and intracavity applications for tumors with known radio sensitivity. On June 1, 2009, the Company expanded its application of Cs-131 with the treatment of a head and neck tumor that could not be accessed by other treatment modalities. IsoRay International LLC (International) is a wholly owned subsidiary of the Company. During fiscal year ended June 30, 2009, the Company divested its ownership in the Russian LLC.

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/16/2014 12:00 AM Buy
None
2.80 5.00
as of 10/17/2014
1 Week down  -4.16 %
1 Month down  -40.00 %
3 Months down  -49.26 %
1 YTD up  176.00 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/1/2013 9:25 AM Buy
None
0.54 1.50

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy